Will CollPlant Biotechnologies (NASDAQ:CLGN) volatility rise before December

CLGN
 Stock
  

USD 4.97  0.06  1.19%   

It seems CollPlant Biotechnologies may not have a good chance to recover from the latest slide as its shares fell again. The company current daily volatility is 3.69 percent, with a beta of 0.19 and an alpha of -0.64 over DOW. While many traders are getting carried away by overanalyzing market volatility, it is reasonable to outline CollPlant Biotechnologies based on how it reacts to the latest economic swings. We will analyze why CollPlant Biotechnologies investors may still consider a stake in the business.
Published six days ago
View all stories for Collplant Biotechnologies | View All Stories
This firm conducts business under Healthcare sector and is part of Biotechnology industry.
The firm shows a Beta (market volatility) of 0.1888, which signifies not very significant fluctuations relative to the market. Let's try to break down what CollPlant's beta means in this case. As returns on the market increase, CollPlant Biotechnologies returns are expected to increase less than the market. However, during the bear market, the loss on holding CollPlant Biotechnologies will be expected to be smaller as well. Even though it is essential to pay attention to CollPlant Biotechnologies historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. CollPlant Biotechnologies exposes twenty-eight different technical indicators, which can help you to evaluate its performance. CollPlant Biotechnologies has an expected return of -0.64%. Please be advised to confirm CollPlant Biotechnologies total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power to decide if CollPlant Biotechnologies performance from the past will be repeated at some point in the near future.
Investing in Collplant Biotechnologies, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Collplant Biotechnologies along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Collplant Biotechnologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Collplant Biotechnologies in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Collplant Biotechnologies. Your research has to be compared to or analyzed against Collplant Biotechnologies' peers to derive any actionable benefits. When done correctly, Collplant Biotechnologies' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Collplant Biotechnologies.

How important is Collplant Biotechnologies's Liquidity

Collplant Biotechnologies financial leverage refers to using borrowed capital as a funding source to finance Collplant Biotechnologies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Collplant Biotechnologies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Collplant Biotechnologies's total debt and its cash.

How does Collplant utilize its cash?

To perform a cash flow analysis of Collplant Biotechnologies, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Collplant Biotechnologies is receiving and how much cash it distributes out in a given period. The Collplant Biotechnologies cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Collplant Biotechnologies Correlation with Peers

Investors in Collplant can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Collplant Biotechnologies. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Collplant Biotechnologies and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Collplant is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Collplant for more details

What is driving Collplant Biotechnologies Investor Appetite?

CollPlant Biotechnologies secures Sharpe Ratio (or Efficiency) of -0.17, which signifies that the company had -0.17% of return per unit of risk over the last 3 months. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. CollPlant Biotechnologies exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm CollPlant Biotechnologies risk adjusted performance of (0.24), and Mean Deviation of 2.73 to double-check the risk estimate we provide.

CollPlant Biotechnologies has 96 percent odds to go over $5.21 this year

Latest information ratio indicator falls down to -0.19. Possible price upswing? CollPlant Biotechnologies exhibits very low volatility with skewness of -0.1 and kurtosis of 0.16. However, we advise investors to further study CollPlant Biotechnologies technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure CollPlant Biotechnologies' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact CollPlant Biotechnologies' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on CollPlant Biotechnologies

Whereas some other firms in the biotechnology industry are either recovering or due for a correction, CollPlant Biotechnologies may not be performing as strong as the other in terms of long-term growth potentials. To sum up, as of the 24th of November 2022, we believe that at this point, CollPlant Biotechnologies is somewhat reliable with low probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 90 days recommendation on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Collplant Biotechnologies. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com